{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.9","value":"32800"},{"groupId":"OG001","spread":"471.1","value":"160000"},{"groupId":"OG002","spread":"546.9","value":"547000"},{"groupId":"OG003","spread":"83.8","value":"2710000"},{"groupId":"OG004","spread":"67.7","value":"5780000"},{"groupId":"OG005","spread":"272.9","value":"603000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"285970.0","value":"10400"},{"groupId":"OG001","spread":"159.8","value":"1920000"},{"groupId":"OG002","spread":"114.5","value":"4780000"},{"groupId":"OG003","spread":"79.6","value":"19300000"},{"groupId":"OG004","spread":"92.1","value":"27000000"},{"groupId":"OG005","spread":"33.9","value":"2690000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Week 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Mezagitamab 45 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG000","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 45 mg"},{"description":"Mezagitamab 135 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG001","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 135 mg"},{"description":"Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG002","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 300 mg"},{"description":"Mezagitamab 600 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG003","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 600 mg"},{"description":"Mezagitamab 1200 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG004","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 1200 mg"},{"description":"Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, at product-labelled dose, orally, once daily on Days 1 to 21 and dexamethasone, at product-labelled dose, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD.","id":"OG005","title":"Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included those participants from the safety analysis set who had sufficient dosing data and mezagitamab concentration-time data to permit the calculation of PK parameters. Overall number analyzed is the number of participants available for analyses. Number analyzed is the number of participants with data available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and 2: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (cycle length=28 days)","title":"AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-079","type":"SECONDARY","unitOfMeasure":"hours*nanogram/milliliter (h*ng/mL)"}